Pivotal bioVenture Partners Investment Advisor LLC Portfolio

Auto-discovered active 13F filer.

SEC 13F CIK: 0001844645

What is a 13F filing? Who files one and when · What 13F filings can't tell you

SmallFocusedHealth TiltHigh Turnover how tags are computed

Q4 2024 · 11 positions · Total reported value $148.07M · Top-10 concentration 99.5% · Updated 2026-10-18

Last updated: 2026-10-18 · Source: SEC EDGAR Form 13F-HR

Turnover: 35.7% · 1 new · 3 cut · 1 exited

Active Share (vs S&P 500): 100.0% · vs QQQ: 100.0% — share of the book that differs from index weights (higher = more active) · ranking

Est. Qtr Return (Q2 2026 → Q3 2026): -13.9% · vs SPY -16.0% · Prev Value $307.79M — last quarter positions weighted by this quarter price moves · ranking

Est. QTD Return (Q3 2026 → newest close): -0.7% · vs SPY -2.9% · Latest Value $245.36M — latest reported positions valued at quarter-to-date price moves (still in progress) · ranking

In its Q4 2024 13F filing, Pivotal bioVenture Partners Investment Advisor LLC disclosed 11 equity positions with a combined reported value of $148.07M. The filing implies a focused portfolio: its ten largest positions account for 99.5% of reported value. HoldingsHub classifies the profile as Small / Focused / Health Tilt / High Turnover.

The largest disclosed positions as of Q4 2024 were PCVX ($57.62M), OCS ($29.54M), ARQT ($29.54M). By sector, the heaviest allocations are Health Care 90.4%, Other 9.6%. Versus the prior quarter, allocation shifted toward Health Care (+8.3pp) and away from Other (-8.3pp).

Versus the prior quarter, Pivotal bioVenture Partners Investment Advisor LLC opened 1 new positions, trimmed 3 and fully exited 1, a turnover rate of 35.7% of positions. The portfolio's overlap with the prior quarter was 83% of names.

The largest new positions opened in Q4 2024 were RXRX ($4.03M).

Of the 1 positions fully exited versus the prior quarter, the largest were EXAI ($3.76M).

Figures come from the fund's SEC Form 13F filing. 13F reports are filed within 45 days of quarter end and cover long positions of $100,000 or more; they exclude short positions and non-13F asset classes, so treat this page as a quarter-end snapshot rather than the fund's live book.

New Positions (Q4 2024)

  • RXRX RECURSION PHARMACEUTICALS IN · $4.03M

Fully Exited (vs previous quarter)

  • EXAI EXSCIENTIA PLC · prev qtr: $3.76M

Insider Transactions (Form 4)

Latest Pivotal bioVenture Partners Investment Advisor LLC buys and sells reported on SEC Form 4 — filed within two business days when the fund's ownership in a stock crosses 10%.

No Form 4 filings for this fund yet — when its ownership in a stock crosses 10%, buys and sells are filed here within two business days.

Fund Profile

Pivotal bioVenture Partners Investment Advisor LLC is an SEC-registered 13F filer. As of Q2 2026 it reported 13 US equity positions with a combined value of $307.79M. HoldingsHub carries 12 quarters of its filings (Q3 2023–Q2 2026).

Portfolio Structure

  • 13 positions · $307.79M reported value (Q2 2026)
  • Top 10 holdings = 95.1% of reported value
  • Largest position: PCVX (VAXCYTE INC) at 26.9%
  • Average position size: $23.68M

Sector Tilt

  • Health Care 100.0%
  • (classified holdings cover 100% of value)

Quarterly Activity

  • Q2 2026: 1 new, 3 added, 3 reduced, 1 exited
  • 6 positions unchanged

Generated from the firm's public SEC Form 13F and ADV filings. It states what the firm has reported — not an evaluation of its strategy, and not investment advice.

Sector Allocation

Health Care 90.4%
Other 9.6%
Sort by: Value · CSV
# Shares Value Weight Allocation Change
1 703.83K $57.62M 38.91%
38.91%
Add
2 1.74M $29.54M 19.95%
19.95%
Add
3 2.12M $29.54M 19.95%
19.95%
Hold
4 4.49M $12.45M 8.41%
8.41%
Hold
5 736.64K $6.03M 4.08%
4.08%
Add
6 595.52K $4.03M 2.72%
2.72%
New
7 653.37K $3.78M 2.56%
2.56%
Add
8 2.40M $2.31M 1.56%
1.56%
Hold
9 1.89M $1.02M 0.69%
0.69%
Hold
10 560.60K $953.01K 0.64%
0.64%
Hold
11 864.20K $795.06K 0.54%
0.54%
Hold

FAQ

What did Pivotal bioVenture Partners Investment Advisor LLC buy in 2024-Q4?

In its 2024-Q4 13F filing, Pivotal bioVenture Partners Investment Advisor LLC reported 11 equity positions worth $148.07M in aggregate; its largest disclosed positions were PCVX ($57.62M), OCS ($29.54M), ARQT ($29.54M).

How large is Pivotal bioVenture Partners Investment Advisor LLC's portfolio?

Pivotal bioVenture Partners Investment Advisor LLC reported $148.07M of long equity holdings across 11 positions as of 2024-Q4. Top-10 holdings account for 99.5% of reported value.

What is Pivotal bioVenture Partners Investment Advisor LLC's investment style?

HoldingsHub classifies the portfolio as Small / Focused / Health Tilt / High Turnover, computed from size, concentration, sector tilt and turnover.

Where does this data come from?

All figures are computed from the fund's SEC Form 13F quarterly filing, which must be filed within 45 days of quarter end for long positions of $100,000 or more.

Embed this fund on your site

Copy the snippet below to show this fund's live top holdings on your blog or forum — free, auto-updating, links back to HoldingsHub.

<iframe src="https://holdingshub.top/funds/pivotal-bioventure-partners-investment-advisor/widget" width="100%" height="520" frameborder="0" loading="lazy" title="HoldingsHub fund holdings"></iframe>

Preview the embeddable widget →